Restoring function after spinal cord injury

Neurologist

Volumn 9, Issue 1, 2003, Pages 1-15

  Becker, Daniel ^a   Sadowsky, Cristina L ^a   McDonald, John W ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Excitotoxicity; Regeneration; Rehabilitation; Spinal cord injury; Stem cell

Indexed keywords

1 (4 AMINOPHENYL) 3,4 DIHYDRO 4 METHYL 3 METHYLCARBAMOYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 6 (1 IMIDAZOLYL) 7 NITRO 2,3 QUINOXALINEDIONE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BACLOFEN; BENZODIAZEPINE DERIVATIVE; CLONIDINE; DANTROLENE; GABAPENTIN; GANGLIOSIDE GM1; LOCAL ANESTHETIC AGENT; METHYLPREDNISOLONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NALOXONE; NIMODIPINE; OPIATE; PROTIRELIN; TIRILAZAD; TIZANIDINE;

CELL REGENERATION; CLINICAL TRIAL; DRUG MEGADOSE; HUMAN; NERVE CELL; NERVE STIMULATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SPINAL CORD INJURY; STEM CELL; SUBSTITUTION THERAPY; SURGICAL TECHNIQUE; TREATMENT OUTCOME;

HUMANS; NERVE REGENERATION; RECOVERY OF FUNCTION; SPINAL CORD INJURIES;

EID: 0037254327     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.nrl.0000038587.58012.05     Document Type: Review

References (171)

1. Go BK, DeVivo MJ, Richards JS. The epidemiology of spinal cord injury. In: Stover SL, DeLisa JA, Whiteneck GG, eds. Spinal Cord Injury: Clinical Outcomes From the Model Systems. Gaichersburg, Md: Aspen; 1990:21-55.
2. Richards JS, Go BK, Rutt RD, et al. The national spinal cord injury database. In: Stover SL, DeLisa JA, Whiteneck GG, eds. Spinal Cord Injury: Clinical Outcomes From the Model Systems. Gaithersburg, Md: Aspen; 1995:10-20.
3. Surkin J, Smith M, Penman A, et al. Spinal cord injury incidence in Mississippi: a capture-recapture approach. J Trauma. 1998;45:502-504.
4. National Spinal Cord Injury Database. Spinal Cord Injury, Facts and Figures. 2001. Birmingham, AL: National Spinal Cord Injury Statistical Center (NSCISC).
5. Tator CH, Fehlings MG. Review of the secondary injury theory of acute spinal cord trauma with emphasis on vascular mechanisms. J. Neurosurg. 1991;75:15-26.
6. Westergren H, Farooque M, Olsson Y, et al. Spinal cord blood flow changes following systemic hypothermia and spinal cord compression injury: an experimental study in the rat using Laser-Doppler flowmetry. Spinal Cord. 2001;39:74-84.
7. Bregman BS, Goldberger ME. Infant lesion effect, 11: sparing and recovery of function after spinal cord damage in newborn and adult cats. Brain Res. 1983;285:119-135.
8. Raineteau O, Schwab ME. Plasticity of motor systems after incomplete spinal cord injury. Nat Rev Neurosci. 2001;2:263-273.
9. McIntosh TK, Juhler M, Wieloch T. Novel pharmacologic strategies in the treatment of experimental traumatic brain injury: J Neurotrauma. 1998;15:731-769.
10. Lee JM, Zipfel GJ, Choi DW. The changing landscape of ischaemic brain injury mechanisms. Nature. 1999;399(suppl):A7-A14.
11. Tator CH, Koyanagi I. Vascular mechanisms in the pathophysiology of human spinal cord injury. J Neurosurg. 1997;86:483-492.
12. Fehlings MG, Tator CH, Linden RD. The effect of nimodipine and dextran on axonal function and blood flow following experimental spinal cord injury. J Neurosurg. 1989;71:403-416.
13. Kobrine AI, Doyle TF, Martins AN. Local spinal cord blood flow in experimental traumatic myelopathy. J Neurosurg. 1975;42:144-149.
14. Matute C, Sanchez-Gomez MV, Martinez-Millan L, et al. Glutamate receptor-mediated toxicity in optic nerve oligodendrocytes. Proc Natl Acad Sci U S A. 1997;94:8830-8835.
15. McDonald JW, Althomsons SP, Hyrc KL, et al. Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity. Nat Med. 1998;4:291-297.
16. Matute C, Alberdi E, Domercq M, et al. The link between excitotoxic oligodendroglial death and demyelinating diseases. Trends Neurosci. 2001;24:224-230.
17. Choi DW. Calcium: still center-stage in hypoxic-ischemic neuronal death. Trends Neurosci. 1995;18:58-60.
18. Beattie MS, Farooqui AA, Bresnahan JC. Review of current evidence for apoptosis after spinal cord injury. J Neurotrauma. 2000;17:915-925.
19. Li GL, Farooque M, Holtz A, et al. Apoptosis of oligodendrocytes occurs for long distances away from the primary injury after compression trauma to rat spinal cord. Acta Neuropathol (Berl). 1999;98:473-480.
20. Kamencic H, Griebel RW, Lyon AW, et al. Promoting glutathione synthesis after spinal cord trauma decreases secondary damage and promotes retention of function. FASEB J. 2001;15:243-250.
21. Casha S, Yu WR, Fehlings MG. Oligodendroglial apoptosis occurs along degenerating axons and is associated with FAS and p75 expression following spinal cord injury in the rat. Neuroscience. 2001;103:203-218.
22. Gard AL, Solodushko VG, Waeg G, et al. 4-Hydroxynonenal, a lipid peroxidation byproduct of spinal cord injury, is cytotoxic for oligodendrocyte progenitors and inhibits their responsiveness to PDGF. Microsc Res Tech. 2001;52:709-718.
23. Crowe MJ, Bresnahan JC, Shuman SL, et al. Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys. Nat Med. 1997;3:73-76.
24. Werner P, Pitt D, Raine CS. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 2001;50:169-180.
25. Werner P, Pitt D, Raine CS. Glutamate excitotoxicity - a mechanism for axonal damage and oligodendrocyte death in Multiple Sclerosis? J Neural Transm Suppl. 2000;60:375-385.
26. Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 2000;6:67-70.
27. Smith T, Groom A, Zhu B, et al. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Med. 2000;6:62-66.
28. Popovich PG, Wei P, Stokes BT. Cellular inflammatory response after spinal cord injury in Sprague- Dawley and Lewis rats. J Comp Neurol. 1997;377:443-464.
29. Schwartz M, Cohen I, Lazarov-Spiegler O, et al. The remedy may lie in ourselves: prospects for immune cell therapy in central nervous system protection and repair. J Mol Med. 1999;77:713-717.
30. Klusman I, Schwab ME. Effects of pro-inflammatory cytokines in experimental spinal cord injury. Brain Res. 1997:762;173-184.
31. Prewitt CM, Niesman IR, Kane CJ, et al. Activated macrophage/microglial cells can promote the regeneration of sensory axons into the injured spinal cord. Exp Neurol. 1997;148:433-443.
32. Hauben E, Nevo U, Yoles E, et al. Autoimmune T cells as potential neuroprotective therapy for spinal cord injury. Lancet. 2000;355:286-287.
33. Hauben E, Agranov E, Gothilf A, et al. Posttraumatic therapeutic vaccination with modified myelin self-antigen prevents complete paralysis while avoiding autoimmune disease. J Clin Invest. 2001;108:591-599.
34. Bunge RP, Puckett WR, Becerra JL, et al. Observations on the pathology of human spinal cord injury: a review and classification of 22 new cases with details from a case of chronic cord compression with extensive focal demyelination. Adv Neurol. 1993;59:75-89.
35. Esce PG, Haines SJ. Acute treatment of spinal cord injury. Curr Treat Options Neurol. 2000;2:517-524.
36. Duh MS, Shepard MJ, Wilberger JE, et al. The effectiveness of surgery on the treatment of acute spinal cord injury and its relation to pharmacological treatment. Neurosurgery. 1994;35:240-248.
37. Dimar JR, Glassman SD, Raque GH, et al. The influence of spinal canal narrowing and timing of decompression on neurologic recovery after spinal cord contusion in a rat model. Spine. 1999;24:1623-1633.
38. Fehlings MG, Sekhon LH, Tator C. The role and timing of decompression in acute spinal cord injury: what do we know? What should we do? Spine. 2001;26(24 suppl):S101-S110.
39. Marshall LF, Knowlton S, Garfin SR, et al. Deterioration following spinal cord injury: a multicenter study. J Neurosurg. 1987;66:400-404.
40. Vaccaro AR, Daugherty RJ, Sheehan TP, et al. Neurologic outcome of early versus late surgery for cervical spinal cord injury. Spine. 1997;22:2609-2613.
41. Chen TY, Dickman CA, Eleraky M, et al. The role of decompression for acute incomplete cervical spinal cord injury in cervical spondylosis. Spine. 1998;23:2398-2403.
42. Mirza SK, Krengel WF III, Chapman JP, et al. Early versus delayed surgery for acute cervical spinal cord injury. Clin Orthop. 1999;359:104-114.
43. Ulrich C, Arand M, Nothwang J. Internal fixation on the lower cervical spine: biomechanics and clinical practice of procedures and implants. Eur Spine J. 2001;10:88-100.
44. Geisler FH. Clinical trials of pharmacotherapy for spinal cord injury. Ann N Y Acad Sci. 1998;845:374-381.
45. Bracken MB, Shepard MJ, Collins WF, et al. Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data. Results of the second National Acute Spinal Cord Injury Study. J Neurosurg. 1992;76:23-31.
46. Bracken MB, Shepard MJ, Collins WF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury: results of the Second National Acute Spinal Cord Injury Study. N Engl J Med. 1990;322:1405-1411.
47. Bracken MB. Methylprednisolone and acute spinal cord injury: an update of the randomized evidence. Spine. 2001;26(24 suppl):S47-S54.
48. Bracken MB, Shepard MJ, Holford TR, et al. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury: results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA. 1997;277:1597-1604.
49. Ducker TB, Zeidman SM. Spinal cord injury: role of steroid therapy. Spine. 1994;19:2281-2287.
50. Nesathurai S. Steroids and spinal cord injury: revisiting the NASCIS 2 and NASCIS 3 trials. J Trauma. 1998;45:1088-1093.
51. Coleman WP, Benzel D, Cahill DW, et al. A critical appraisal of the reporting of the National Acute Spinal Cord Injury Studies (II and III) of methylprednisolone in acute spinal cord injury. J Spinal Disord. 2000;13:185-199.
52. Hurlbert RJ. Methylprednisolone for acute spinal cord injury: an inappropriate standard of care. J Neurosurg. 2000;93(1 suppl):1-7.
53. Fehlings MG. Editorial: recommendations regarding the use of methylprednisolone in acute spinal cord injury: making sense out of the controversy. Spine. 2001;26(24 suppl):S56-S57.
54. Matsumoto T, Tamaki T, Kawakami M, et al. Early complications of high-dose methylprednisolone sodium succinate treatment in the follow-up of acute cervical spinal cord injury. Spine. 2001;26:426-430.
55. Geisler FH, Dorsey FC, Coleman WP. Recovery of motor function after spinal-cord injury: a randomized, placebo-controlled trial with GM-1 ganglioside. N Engl J Med. 1991;324:1829-1838.
56. Geisler FH, Coleman WP, Grieco G, et al. The Sygen multicenter acute spinal cord injury study. Spine. 2001;26(24 suppl):S87-S98.
57. Wrathall JR, Teng YD, Choiniere D. Amelioration of functional deficits from spinal cord trauma with systemically administered NBQX, an antagonist of non-N-methyl-D-aspartate receptors. Exp Neurol. 1996;137:119-126.
58. Stys PK. Anoxic and ischemic injury of myelinated axons in CNS white matter: from mechanistic concepts to therapeutics. J Cereb Blood Flow Metab. 1998;18:22-25.
59. Umemura K, Kondo K, Ikeda Y, et al. Pharmacokinetics and safety of the novel amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist YM90K in healthy men. J Clin Pharmacol. 1997;37:719-727.
60. Lees GJ. Phamlacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders. Drugs. 2000;59:33-78.
61. Burns SP, Golding DG, Rolle WA Jr, et al. Recovery of ambulation in motor-incomplete tetraplegia. Arch Phys Med Rehabil. 1997;78:1169-1172.
62. Waters RL, Sie I, Adkins RH, et al. Injury pattern effect on motor recovery after traumatic spinal cord injury. Arch Phys Med Rehabil. 1995;76:440-443.
63. Wong ST, Atkinson BA, Weaver LC. Confocal microscopic analysis reveals sprouting of primary afferent fibres in rat dorsal horn after spinal cord injury. Neurosci Lett. 2000;296:65-68.
64. Stover SL. Review of forty years of rehabilitation issues in spinal cord injury. J Spinal Cord Med. 1995;18:175-182.
65. Burnham R, Martin T, Stein R, et al. Skeletal muscle fibre type transformation following spinal cord injury. Spinal Cord. 1997;35:86-91.
66. Gerrits HL, de Haan A, Hopman MT, et al. Contractile properties of the quadriceps muscle in individuals with spinal cord injury. Muscle Nerve. 1999;22:1249-1256.
67. Siddall PJ, Loeser JD. Pain following spinal cord injury. Spinal Cord. 2001;39:63-73.
68. Fenollosa P, Pallares J, Cervera J, et al. Chronic pain in the spinal cord injured: statistical approach and pharmacological treatment. Paraplegia. 1993;31:722-729.
69. Glynn CJ, Jamous MA, Teddy PJ, et al. Role of spinal noradrenergic system in transmission of pain in patients with spinal cord injury. Lancet. 1986;2:1249-1250.
70. Sandford PR, Lindblom LB, Haddox JD. Amitriptyline and carbamazepine in the treatment of dysesthetic pain in spinal cord injury. Arch Phys Med Rehabil. 1992;73:300-301.
71. Ness TJ, San Pedro EC, Richards JS, et al. A case of spinal cord injury-related pain with baseline rCBF brain SPECT imaging and beneficial response to gabapentin. Pain. 1998;78:139-143.
72. Loubser PG, Donovan WH. Diagnostic spinal anaesthesia in chronic spinal cord injury pain. Paraplegia. 1991;29:25-36.
73. Eide PK, Stubhaug A, Stenehjem AE. Central dysesthesia pain after traumatic spinal cord injury is dependent on N-methyl-D-aspartate receptor activation. Neurosurgery. 1995;37:1080-1087.
74. Loubser PG, Akman NM. Effects of intrathecal baclofen on chronic spinal cord injury pain. J Pain Symptom Manage. 1996;12:241-247.
75. Loubser PG, Clearman RR. Evaluation of central spinal cord injury pain with diagnostic spinal anesthesia. Anesthesiology. 1993;79:376-378.
76. Friedman AH, Nashold BS Jr. DREZ lesions for relief of pain related to spinal cord injury. J Neurosurg. 1986;65:465-469.
77. Umlauf RL. Psychological interventions for chronic pain following spinal cord injury. Clin J Pain. 1992;8:111-118.
78. Linsenmeyer TA. Sexual function and infertility following spinal cord injury. Phys Med Rehabil Clin North Am. 2000;11:141-156.
79. Sipski ML. Sexual functioning in the spinal cord injured. Int J Impot Res. 1998;10(suppl 2):S128-S130.
80. Biering-Sorensen F, Sonksen J. Sexual function in spinal cord lesioned men. Spinal Cord. 2001;39:455-470.
81. Ekland M, Griffin S, Copeland J, et al. Exploring male fertility options after spinal cord injury: the role of the nurse clinician. SCI Nurs. 1998;15:95-98.
82. Tomassen PC, Post MW, van Asbeck FW. Return to work after spinal cord injury. Spinal Cord. 2000;38:51-55.
83. Freehafer AA. Tendon transfers in tetraplegic patients: the Cleveland experience. Spinal Cord. 1998;36:315-319.
84. Johnstone BR, Jordan CJ, Buntine JA. A review of surgical rehabilitation of the upper limb in quadriplegia. Paraplegia. 1988;26:317-339.
85. Protas EJ, Holmes SA, Qureshy H, et al. Supported treadmill ambulation training after spinal cord injury: a pilot study. Arch Phys Med Rehabil. 2001;82:825-831.
86. Field-Fote EC. Combined use of body weight support, functional electric stimulation, and treadmill training to improve walking ability in individuals with chronic incomplete spinal cord injury. Arch Phys Med Rehabil. 2001;82:818-824.
87. Grill WM, McDonald JW, Peckham PH, et al. At the interface: convergence of neural regeneration and neural prostheses for restoration of function. J Rehabil Res Dev. 2001;38:633-639.
88. Gerrits HL, de Haan A, Sargeant AJ, et al. Peripheral vascular changes after electrically stimulated cycle training in people with spinal cord injury. Arch Phys Med Rehabil. 2001;82:832-839.
89. Belanger M, Stein RB, Wheeler GD, et al. Electrical stimulation: can it increase muscle strength and reverse osteopenia in spinal cord injured individuals? Arch Phys Med Rehabil. 2000;81:1090-1098.
90. Scremin AM, Kurta L, Gentili A, et al. Increasing muscle mass in spinal cord injured persons with a functional electrical stimulation exercise program. Arch Phys Med Rehabil. 1999;80:1531-1536.
91. Nash MS, Montalvo BM, Applegate B. Lower extremity blood flow and responses to occlusion ischemia differ in exercise-trained and sedentary tetraplegic persons. Arch Phys Med Rehabil. 1996;77:1260-1265.
92. Stein RB. Functional electrical stimulation after spinal cord injury. J Neurotrauma. 1999;16:713-717.
93. Carter RE, Donovan WH, Halstead L, et al. Comparative study of electrophrenic nerve stimulation and mechanical ventilatory support in traumatic spinal cord injury. Paraplegia. 1987;25:86-91.
94. Glenn WW, Phelps ML, Elefteriades JA, et al. Twenty years of experience in phrenic nerve stimulation to pace the diaphragm. Pacing Clin Electrophysiol. 1986;9(6 pt 1):780-784.
95. DiMarco AF. Neural prostheses in the respiratory system. J Rehabil Res Dev. 2001;38:601-607.
96. Creasey GH, Dahlberg JE. Economic consequences of an implanted neuroprosthesis for bladder and bowel management. Arch Phys Med Rehabil. 2001;82:1520-1525.
97. Creasey GH, Grill JH, Korsten M, et al. An implantable neuroprosthesis for restoring bladder and bowel control to patients with spinal cord injuries: a multicenter trial. Arch Phys Med Rehabil. 2001;82:1512-1519.
98. Peckham PH, Keith MW, Kilgore KL, et al. Efficacy of an implanted neuroprosthesis for restoring hand grasp in tetraplegia: a multicenter study. Arch Phys Med Rehabil. 2001;82:1380-1388.
99. Keith MW, Kilgore KL, Peckham PH, et al. Tendon transfers and functional electrical stimulation for restoration of hand function in spinal cord injury. J Hand Surg [Am]. 1996;21:89-99.
100. Fromm B, Rupp R, Gerner HJ. The Freehand System: an implantable neuroprosthesis for functional electrostimulation of the upper extremity [in German]. Handchir Mikrochir Plast Chir. 2001;33:149-152.
101. Keith MW. Neuroprostheses for the upper extremity. Microsurgery. 2001;21:256-263.
102. Triolo RJ, Liu MQ, Kobetic R, et al. Selectivity of intramuscular stimulating electrodes in the lower limbs. J Rehabil Res Dev. 2001;38:533-544.
103. Shoham S, Halgren E, Maynard EM, et al. Motor-cortical activity in tetraplegics. Nature. 2001;413(6858):793.
104. Nicolelis MA. Actions from thoughts. Nature. 2001;409:403-407.
105. Wessberg J, Stambaugh CR, Kralik JD, et al. Real-time prediction of hand trajectory by ensembles of cortical neurons in primates. Nature. 2000;408:361-365.
106. Kennedy PR, Bakay RA, Moore MM, et al. Direct control of a computer from the human central nervous system. IEEE Trans Rehabil Eng. 2000;8:198-202.
107. Bhadra N, Kilgore KL, Peckham PH. Implanted stimulators for restoration of function in spinal cord injury. Med Eng Phys. 2001;23:19-28.
108. Blight AR. Cellular morphology of chronic spinal cord injury in the cat: analysis of myelinated axons by line-sampling. Neuroscience. 1983; 10:521-543.
109. Schwab ME. Repairing the injured spinal cord. Science. 2002;295:1029-1031.
110. Hauser RA, Furtado S, Cimino CR, et al. Bilateral human fetal striatal transplantation in Huntington's disease. Neurology. 2002;58:687-695.
111. Bachoud-Levi AC, Remy P, Nguyen JP, et al. Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet. 2000;356:1975-1979.
112. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med. 2001; 344:710-719.
113. Piccini P, Lindvall O, Bjorklund A, et al. Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Ann Neurol. 2000;48:689-695.
114. Piccini P, Brooks DJ, Bjorklund A, et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci. 1999;2:1137-1140.
115. Hauser RA, Freeman TB, Snow BJ, et al. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch Neurol. 1999;56:179-187.
116. Falci S, Holtz A, Akesson E, et al. Obliteration of a posttraumatic spinal cord cyst with solid human embryonic spinal cord grafts: first clinical attempt. J Neurotrauma. 1997;14:875-884.
117. Brevig T, Holgersson J, Widner H. Xenotransplantation for CNS repair: immunological barriers and strategies to overcome them. Trends Neurosci. 2000;23:337-344.
118. Melton L. Neural transplantation: new cells for old brains. Lancet. 2000;355(9221):2142.
119. von Meyenburg J, Brosamle C, Metz GA, et al. Regeneration and sprouting of chronically injured corticospinal tract fibers in adult rats promoted by NT-3 and the mAb IN-1, which neutralizes myelin-associated neurite growth inhibitors. Exp Neurol. 1998;154:583-594.
120. Schwab ME, Caroni P. Oligodendrocytes and CNS myelin are nonpermissive substrates for neurite growth and fibroblast spreading in virro. J Neurosci. 1988;8:2381-2393.
121. Chen MS, Huber AB, van der Haar ME, et al. Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. Nature. 2000;403:434-439.
122. Schwab ME, Bartholdi D. Degeneration and regeneration of axons in the lesioned spinal cord. Physiol Rev. 1996;76:319-370.
123. Brittis PA, Flanagan JG. Nogo domains and a Nogo receptor: implications for axon regeneration. Neuron. 2001;30:11-14.
124. Shifman MI, Selzer ME. Expression of the netrin receptor UNC-5 in lamprey brain: modulation by spinal cord transection. Neurorehabil Neural Repair. 2000;14:49-58.
125. McDonald JW. Repairing the damaged spinal cord. Sci Am. 1999;281:64-73.
126. Jones LL, Oudega M, Bunge MB, et al. Neurotrophic factors, cellular bridges and gene therapy for spinal cord injury. J Physiol. 2001;533(pt 1):83-89.
127. Li H, Zou X, Bunger C. Gene therapy and spinal disorders. Int Orthop. 2001;25:11-4.
128. Smith GM, Romero MI. Adenoviral-mediated gene transfer to enhance neuronal survival, growth, and regeneration. J Neurosci Res. 1999;55:147-157.
129. Rabchevsky AG, Smith GM. Therapeutic interventions following mammalian spinal cord injury. Arch Neurol. 2001;58:721-726.
130. Shibata M, Murray M, Tessler A, et al. Single injections of a DNA plasmid that contains the human Bcl-2 gene prevent loss and atrophy of distinct neuronal populations after spinal cord injury in adult rats. Neurorehabil Neural Repair. 2000;14:319-330.
131. Blakemore WF. Remyelination of CNS axons by Schwann cells transplanted from the sciatic nerve. Nature. 1977;266:68-69.
132. Kromer LF, Combrooks CJ. Transplants of Schwann cell cultures promote axonal regeneration in the adult mammalian brain. Proc Natl Acad Sci U S A. 1985;82:6330-6334.
133. Morrissey TK, Bunge RP, Kleitman N. Human Schwann cells in vitro, I: Failure to differentiate and support neuronal health under co-culture conditions that promote full function of rodent cells. J Neurobiol. 1995;28:171-189.
134. Oudega M, Xu XM, Guenard V, et al. A combination of insulin-like growth factor-I and platelet-derived growth factor enhances myelination but diminishes axonal regeneration into Schwann cell grafts in the adult rat spinal cord. Glia. 1997; 19:247-258.
135. Xu XM, Guenard V, Kleitman N, et al. Axonal regeneration into Schwann cell-seeded guidance channels grafted into transected adult rat spinal cord. J Comp Neurol. 1995;351:145-160.
136. Verdu E, Garcia-Alias G, Fores J, et al. Effects of ensheathing cells transplanted into photochemically damaged spinal cord. Neuroreport. 2001;12:2303-2309.
137. Akesson E, Holmberg L, Jonhagen ME, et al. Solid human embryonic spinal cord xenografts in acute and chronic spinal cord cavities: a morphological and functional study. Exp Neurol. 2001;170:305-316.
138. Zurita M, Vaquero J, Oya S, et al. Functional recovery in chronic paraplegic rats after co-grafts of fetal brain and adult peripheral nerve tissue. Surg Neurol. 2001;55:249-254.
139. Teng YD, Lavik EB, Qu X, et al. Functional recovery following traumatic spinal cord injury mediated by a unique polymer scaffold seeded with neural stem cells. Proc Natl Acad Sci U S A. 2002;99:3024-3029.
140. Liu S, Qu Y, Stewart TJ, et al. Embryonic stem cells differentiate into oligodendrocytes and myelinate in culture and after spinal cord transplantation. Proc Natl Acad Sci U S A. 2000;97:6126-6131.
141. McDonald JW, Liu XZ, Qu Y, et al. Transplanted embryonic stem cells survive, differentiate and promote recovery in injured rat spinal cord. Nat Med. 1999;5:1410-1412.
142. Lois C, Alvarez-Buylla A. Proliferating subventricular zone cells in the adult mammalian forebrain can differentiate into neurons and glia. Proc Natl Acad Sci U S A. 1993;90:2074-2077.
143. Morshead CM, Reynolds BA, Craig CG, et al. Neural stem cells in the adult mammalian forebrain: a relatively quiescent subpopulation of subependymal cells. Neuron. 1994;13:1071-1082.
144. Reynolds BA, Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science. 1992;255:1707-1710.
145. Chalmers-Redman RM, Priestley T, Kemp JA, et al. In vitro propagation and inducible differentiation of multipotential progenitor cells from human fetal brain. Neuroscience. 1997;76:1121-1128.
146. Moyer MP, Johnson RA, Zompa EA, et al. Culture, expansion, and transplantation of human fetal neural progenitor cells. Transplant Proc. 1997;29:2040-2041.
147. Svendsen CN, Caldwell MA, Shen J, et al. Long-term survival of human central nervous system progenitor cells transplanted into a rat model of Parkinson's disease. Exp Neurol. 1997;148:135-146.
148. Akiyama Y, Honmou O, Kato T, et al. Transplantation of clonal neural precursor cells derived from adult human brain establishes functional peripheral myelin in the rat spinal cord. Exp Neurol. 2001; 167:27-39.
149. Vaughn JE, Peters A. A third neuroglial cell type: an electron microscopic study. J Comp Neurol. 1968;133:269-288.
150. Raff MC, Miller RH, Noble M. A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium. Nature. 1983;303:390-396.
151. Keirstead HS, Blakemore WF. Identification of post-mitotic oligodendrocytes incapable of remyelination within the demyelinated adult spinal cord. J Neuropathol Exp Neurol. 1997;56:1191-1201.
152. Carroll WM, Jennings AR, Ironside LJ. Identification of the adult resting progenitor cell by autoradiographic tracking of oligodendrocyte precursors in experimental CNS demyelination. Brain. 1998;121 (pt 2):293-302.
153. Redwine JM, Armstrong RC. In vivo proliferation of oligodendrocyte progenitors expressing PDGFαR during early remyelination. J Neurobiol. 1998;37:413-428.
154. Gensert JM, Goldman JE. Endogenous progenitors remyelinate demyelinated axons in the adult CNS. Neuron. 1997;19:197-203.
155. Fawcett JW, Asher RA. The glial scar and central nervous system repair. Brain Res Bull. 1999;49:377-391.
156. McKeon RJ, Hoke A, Silver J. Injury-induced proteoglycans inhibit the potential for laminin-mediated axon growth on astrocytic scars. Exp Neurol. 1995;136:32-43.
157. Kopen GC, Prockop DJ, Phinney DG. Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proc Natl Acad Sci U S A. 1999;96:10711-10716.
158. Woodbury D, Schwarz EJ, Prockop DJ, et al. Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res. 2000;61:364-370.
159. Sasaki M, Honmou O, Akiyama Y, et al. Transplantation of an acutely isolated bone marrow fraction repairs demyelinated adult rat spinal cord axons. Glia. 2001;35:26-34.
160. Morshead CM, Benveniste P, Iscove NN, et al. Hematopoietic competence is a rare property of neural stem cells that may depend on genetic and epigenetic alterations. Nat Med. 2002;8:268-273.
161. D'Amour KA, Gage FH. Are somatic stem cells pluripotent or lineage-restricted? Nat Med. 2002;8:213-214.
162. Donovan PJ, Gearhart J. The end of the beginning for pluripotent stem cells. Nature. 2001;414:92-97.
163. Stephenson J. Green light for federally funded research on embryonic stem cells. JAMA. 2000;284:1773-1774.
164. Kempermann G, Gage FH. New nerve cells for the adult brain. Sci Am. 1999;280:48-53.
165. van der SM, Veldhuis WB, van Haaften GW, et al. Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J Neurosci. 2001;21:8765-8771.
166. Huang J, Agus DB, Winfree CJ, et al. Dehydroascorbic acid, a blood-brain barrier transportable form of vitamin C, mediates potent cerebroprotection in experimental stroke. Proc Natl Acad Sci U S A. 2001;98:11720-11724.
167. Satoh S, Utsunomiya T, Tsurui K, et al. Pharmacological profile of hydroxy fasudil as a selective rho kinase inhibitor on ischemic brain damage. Life Sci. 2001;69:1441-1453.
168. Smith-Swintosky VL, Zhao B, Shank RP, et al. Topiramate promotes neurite outgrowth and recovery of function after nerve injury. Neuroreport. 2001;12:1031-1034.
169. de Haan P, Kalkman CJ, Jacobs MJ. Pharmacologic neuroprotection in experimental spinal cord ischemia: a systematic review. J Neurosurg Anesthesiol. 2001;13:33-12.
170. McDonald JW, Sadowsky C. Spinal-cord injury. Lancet. 2002;359:417-425.
171. McDonald JW, Becker D, Sadowsky CL, Jane JA Sr, Conturo TE, Schultz LM. Late recovery following spinal cord injury. Case report and review of the literature. J Neurosurg 2002;97(2 Suppl):252-265.